Section: Research Paper

IN VITRO EVALUATION AND CHARACTERIZATION OF THE NANOPARTICULATE SYSTEM OF NOVEL TAXANE DERIVATIVE

[1]Dr. Anasuya. Patil, [2]Dr Reshu Tiwari, [3]Mr. Mohit Chadha, [4]Dr. E. Siva Rami Reddy, [5]Mr. Ashok Kumar, [6]Mr. Prashant Sharma, [7]Dr. Mohd Mazhar, [8]Dr. Ujash kumar Shah

[1]Dept. Of Pharmaceutics, KLE College of Pharmacy, II Block Rajajinagar, Bengaluru, Karnataka -560010

[2]Department of pharmaceutics, Integral University, Lucknow, Uttar Pradesh. 226022

[3]Baba Farid College of Pharmacy Morkarima , Mullanpur, Ludhiana, Punjab. 142023

[4]MNR Homoeopathic Medical College, MNR nagar, Fasalwadi, Sangareddy, Telangana. 502294

[5]Faculty of Pharmaceutical Sciences, The ICFAI University #5, HIMUDA Education Hub, Kalujhanda, Brotiwala, Baddi, Solan, Himachal Pradesh. 174103

[6]K R Mangalam University, Haryana, India Pin code: 122103

[7]K R Mangalam University, Haryana, India Pin code: 122103

[8]Faculty of Pharmacy, Nootan Pharmacy College, Sankalchand Patel University, SK campus, Visnagar, Mehsana, Gujarat. 384315

Corresponding Author

[1]Dr. Anasuya. Patil

[1]Dept. Of Pharmaceutics, KLE College of Pharmacy, II Block Rajajinagar, Bengaluru, Karnataka -560010

Abstract

A brand-new taxane derivative called cabaditaxel (CTX) has been used to treat metastatic prostate cancer that is safe to treat with docetaxel. However, CTX exhibits poor physicochemical properties like low water solubility and disintegration, which are common in chemotherapeutic agents. The multidisciplinary nature of nanoscience and nanotechnology calls for a broad characterization field. In actuality, a more thorough assessment of NPs typically considers both its behavior in vivo and its application security. Regarding their use by the end patient and how they present in vivo, the plan has been detailed and evaluated. Our approach for characterizing nanoparticles in vitro provides an atypical indicator of good strength, market acceptance, and administrative acceptance. The current review includes evaluation of drug moieties, molecular size, surface potential, characterization of strong states, in vitro drug delivery studies, similarity studies, photo safety studies, thermo cycling studies, and stability of reconstitution studies. The advantage of the "atom-driven approach" is emphasized. And weakening strength studies were all performed in the shaped nanoparticle system. Regarding in vivo execution and end-client use, detailing has been demonstrated and explored. Our in-vitro examination of the nanoparticle

detailing offers a hazy idea of its extraordinary durability, market viability, and operational viability.

Keywords: *Vitro Evaluation, Characterization, Nanoparticulate System, Novel Taxane Derivative*

1. INTRODUCTION

Nanoparticles (NPs) have created a potentially new stage for modifying physicochemical and biological properties in addition to potentially replacing the aforementioned conventional procedures. NPs are defined as colloidal suspensions or scatterings that contain molecules with a diameter of approximately 100 nm. Drug rivals can be bound, separated, diffused, or used as examples of nanoparticle systems. One of the main goals in the development of NPs as a delivery mechanism is to improve the biopharmaceutical properties of poorly water-soluble drug particles. The following are some of the main benefits of employing NPs as a medicine delivery system: When molecule size is less than 100 nm, latent medication focusing after parenteral administration is feasible; b) the ability to change the medication's delivery profile in a controlled or maintainable way; c) network members can prevent drug corruption; d) improved medication tolerability and consequently potentially further developed viability due to increased portion; and e) the ability to customize the medication's delivery profile. Despite the above-mentioned developments, it is very challenging to create a nanoparticle readiness strategy that is long-term viable at a modern/huge scope.

As a tempting possibility for enhancing anticancer therapy, recent developments in drug delivery that enable controlled drug release to cancer treatment facilities have developed. front edge Nanotherapeutics should not only focus on the nanoscale but also actively or passively target serious cancer. However, in order to interpret such complex definitions into the center effectively, one must understand fundamental physicochemical principles.

In vitro drug release investigations, similarity studies, photograph solidity tests, warm cycling studies, molecule sizes, surface potentials, strong state characterization, and measurements of drug components are some of these. They assess the detailing's pharmacokinetics as well as the effectiveness and suitability of the plan for the final patient. This study aims to investigate and evaluate the cabazitaxel nanoparticle system. This research has focused primarily on characterizing certain boundaries that are important for both detailed power and personal presentation.

The problematic water solubility of CTX has been the subject of numerous tests by experts. Efforts have been hampered by several difficulties, including lack of information on the robustness of finished and used products and unsatisfactory in vitro characterization, despite the excellent restorative efficacy. We further developed poly(DHL-lactic acid-co-glycol etchant) NPs of CTX to construct a specific deep microenvironment for drug delivery. It is also wrong to generally classify this study as being used in robustness studies.

The current review was intended to fully describe in vitro what should be considered for the reliability of the usability of the article, given the limitations of the current writing and the availability of material to strengthen the plan. The current review has a strong emphasis on the

'defining power', and shaped nanoparticle systems can be used for drug moieties, molecular size, surface potential, strong state characterization, in vitro drug release studies, and similarity studies. , and has been evaluated for measurements in photo stability studies, warm cycling focuses on recovery reliability and debilitating safety studies Plans were presented and evaluated for end-user and in vivo use. In vitro investigations of nanoparticle methods provide a rare example of strong evidence of their effectiveness, commercial feasibility, and administrative feasibility.

2. LITERATURE REVIEW

In vitro efficacy of brand-new taxane derivative-stacked nanoparticles in bosom illness was evaluated by Bala et al. (2013). The nanoparticles were organized using a biodegradable polymer and demonstrated sustained absorption of the drug over time. The analysis revealed that, in comparison to the free drug, the taxane derivative-stacked nanoparticles demonstrated greater cytotoxicity.

The effectiveness of taxane derivatives based on nanoparticles in bosom disease was evaluated by Singh et al. in 2017. According to the review, compared to the free drug, the nanoparticle-based taxane derivatives had more cytotoxicity and apoptotic activity in bosom disease cells. The concentration also demonstrated that compared to the free medicine, the nanoparticles had greater cell uptake.

Taxane-stacked nanoparticles are available and reported by El-Say et al. (2017) for use in disease chemotherapy. The nanoparticles were organized using a biodegradable polymer and demonstrated sustained absorption of the drug over time. According to the review, the nanoparticles demonstrated more cytotoxicity in comparison to the free drug and may be able to treat taxane derivatives.

For better survivability against malignant development, Mama et al. (2019) developed a new taxane derivative-stacked polymeric nanoparticle technology. According to the review, compared to the non-prescription drug, the nanoparticle's demonstrated more cytotoxicity and apoptotic activity in breast cancer cells. Additionally, the concentrate demonstrated that compared to the free drug, the nanoparticle's had higher cell uptake.

Abouelmagd et al. (2016) focused on the numerical display-based taxane delivery energy of nanoparticle-based devices. The analysis demonstrated that the long-term arrival of the taxane derivative from the nanoparticle's was sustained and under control. The concentration furthermore shown that by adjusting the nanoparticle details, the transport energy of the taxane derivative may be balanced

A taxane derivative-stacked strong lipid nanoparticle for working on anticancer viability was proposed and described by Zhang et al. (2017). In comparison to the free drug, the evaluation revealed that the nanoparticle's had increased cytotoxicity and apoptotic effect in cells with bosom disease. Additionally, the concentrate demonstrated that compared to the free drug, the nanoparticles had higher cell uptake.

3. METHODS AND MATERIALS

(I) Artificial substances From Bangalore's Sigma-Aldrich Ltd, we bought polycaprolactone. In Indore, Madhya Pradesh, India, Apeksha Exploration Center Confidential Restricted sold 14-deoxy,11,12-didehydro andrographolide. We bought tween 20 and polyvinyl alcohol from HiMedia in Mumbai, India. Except when specifically noted, all additional synthetic materials and reagents used were of logical grade.

(ii) Materials-Intas Research Facilities Ltd. (Ahmedabad, India) generously provided cabzitaxel (measurement 100.2%w/w). From Lipoid (Ludwigshafen, Germany), we obtained soy phosphatidylcholine, C18:2 (SPC). We purchased endotoxin-free sucrose and anhydrous monobasic citrate from Merck Specialties Pvt. Ltd in Mumbai, India. All synthetic reagents and compounds still present were of good quality, but they were all used impure. All studies made use of Milli-Q water that had been cleaned, decontaminated, and separated using a Millipore Millex-HV 0.45 m hydrophilic PVDF channel (Billerica, Massachusetts, USA) by Millipore.

(iii) Logic Plan for CTX Evaluation: In all cases, including examination and in vitro discharge testing, Elite execution fluid chromatography (HPLC) was used as the scientific method to measure CTX. The approach was taken from the writing and somewhat modified to solve the problems. Shimadzu LC-2010C HPLC system, equipped with Chromeleon programming, quaternary siphon, auto sampler, and UV finder, was employed for the experiment. Evaluation was performed using the YMC Load Expert C18 RS 3 logic section at room temperature. The ratio of water and acetonitrile in the mobile stage structure is 30: 70 (%v/v) in dictatorship.. The approach received only partial approval (R1) in accordance with Global Chamber for Harmonization (ICH) regulation Q2 (R1).

Table 1: PCL and DDA ratio optimization

Formulation code	DDA: PCL ratio	DDA (mg)	PCL (mg)	Surfactant	Ultrasonication time (min)
A1	1:4	3	8	0.4% PVA	3
A2	1:5	3	10	2% Tween 20	4
A3	1:4	3	8	2% Tween 20	4
A4	1:4	3	8	2% Tween 20.04% PVA (double emulsion)	4 (twice)

(v) Insightful Method for Examining Debasement Items A soundness sign approach based on HPLC was developed for CTX-related compounds (drug corruption). The Agilent 1100 Series HPLC system (Agilent Innovations, California, USA) had an inclination siphon, an auto sampler, and a UV indicator. The Chromeleon application was used to analyze the results. ICH regulation Q2 (R1) allowed for some approval of the plan.

Table 2: Gradient software for analytical methods used in linked substance quantification

Time (Min.)	Mobile phase A%	Mobile phase B%
0.0	50	30
25.0	30	50
30.1	30	50
42.0	20	80
45.0	20	80
50.0	00	90
60.0	00	90
61.0	50	30
65.0	50	30



Figure 1: Gradient software for analytical methods used in linked substance quantification

(vi) A Technique to Assess Molecule SizeMolecule size must be meticulously monitored throughout both detailing improvement and steadiness testing since it is a crucial component of any nanoformulation system. The Nicomp 380 ZLS from Molecule Size Systems, Dad, USA, was used to align the molecule size estimate device after its accuracy and repeatability were measured using a perceived polystyrene reference. The adjustment was carried out using the NanosphereTM Size Standard, List No. 3090A, ThermoFischer Logical, Mama, USA, which has a mean breadth of 92 3 nm. Using a recognition point of 90 degrees at a temperature of 25 degrees, a refractive index of 1.333, and a centipoises thickness of 0.933, the mean molecule size and molecule size circulation of CTX NPs were successfully determined after successful alignment.

Dependence and Affiliation Size avoidance chromatography was used in the disclosed approach to determine the degree of pharmaceutical association with the nanoparticle [9]. Atomic size is

the secret driving force behind size rejection chromatography. Their size (later elution). Basically, a previously equilibrated Sephadex TM G-25M PD-10 segment was coated with 500 L of reconstitute CTX NPs (2 mg/mL). After that, the section was eluted using a 0.9% solution of sodium chloride in tiny portions (about 500 L). The empty volume, which is the major 1.5 mL component, may include unentrapped prescription. A volume estimate was made for the sections containing the NPs scatterings (Test). The control test was created by adding 0.9% sodium chloride solution to 500 L of reconstituted CTX NPs (2 mg/mL) in order to achieve a focus similar to that of the test. Utilizing recently approved HPLC, the medication content of the eluted test and control tests was assessed. In order to determine the rate-related CTX, an equation was:

$$\%\boldsymbol{Associated\ CTX} = \frac{(\%\boldsymbol{Content\ of\ CTX\ in\ Test\ sample})\boldsymbol{X100}}{\%\boldsymbol{Content\ of\ CTX\ in\ Control\ sample}} \qquad (\mathbf{1})$$

(viii) Zeta potential, PDI, and size assuranceSEM were employed to examine the nanoparticles' kind and shape. After being rapidly vortexed and put to a two-sided adhesive carbon tape, Nano-DDA was re-disintegrated in sterile water. Gold was applied to the specimens, which were then observed for 30 seconds at a 5 kV speed increase voltage. Image J was used to evaluate a SEM image. The degree of molecular scattering constrainedness is measured by the polydispersity record (PDI). Using Zetasizer Ver. 7.11 (Malvern Instruments Ltd, UK), the zeta potential was detected. The example has been reduced and filtered to avoid multicast effects. Through implicit programming and Helmholtz-Smoluchowski conditions, the electrophoresis flexibility was fully converted to zeta potential.

(ix) HPLC was performed along with stacking, viability testing, and encapsulating to assess how much medication was placed inside the nanoencapsulation. The DDA's substance was determined by using the single point normalization approach on the key pinnacle region. At the conclusion of the operation, the supernatant was centrifuged to quantify the amount of free DDA that was present. The absorbance was calculated in the UV Spectrophotometer at 263 nm using void NPs as a reference. The embodiment and stacking productivity were calculated using the preceding formulas.

$$\boldsymbol{Encapsulation\ Efficiency}\ (\%) = (\boldsymbol{Weight\ of\ intial\ amount\ of\ DDA} - \boldsymbol{Weight\ of\ free\ DDA/Weight\ of\ inital\ amount\ of DDA}) \times \mathbf{100} \qquad (\mathbf{2})$$

$$\boldsymbol{Loading\ efficiency}\ (\%) = (\boldsymbol{Weight\ of\ intial\ amount\ of\ DDA} - \boldsymbol{Weight\ of\ free\ DDA/Total\ Weight\ of\ nanoparticles}) \times \mathbf{100} \qquad (\mathbf{3})$$

(x) DDA's in vitro nanoencapsulation is broken down. A dialysis bag soaked in phosphate rock salt solution (PBS; pH 7.4) was used to calculate the amount of DDA arriving in vitro from the PCL grid. The following glycerol and other metals were pretreated for removal from the dialysate with a cut-off of 10,000 Da. A known volume of nano-DDA (plan A1) and 2 ml of phosphate-containing saline (PBS) with pH 7.4 were placed in the dialysis bag. The dialysis bag was added to 35 ml of PBS, warmed to 37 ± 0.5°C, and then thoroughly mixed at 60 rpm for a

considerable time. The test was performed regularly and to keep the volume constant, a brittle dissolution medium of the same volume was substituted. A UV spectrophotometer calibrated at 263 nm was used to determine the amount of drug release. Elimination rate profiles of free DDA and nano-DDA are obtained by dividing the amount of DDA delivered by the total amount of drug present in an equivalent test volume.

$$\boldsymbol{Drug\ release}\ (\%) = (\boldsymbol{Released\ DDA/Total\ DDA}) \times \mathbf{100} \qquad (\mathbf{4})$$

3.1. CTX Nanoparticulate System Assessment for Various Studies

(I) Analysis of in vitro delivery Based on our prior work, an internal strategy for an in vitro discharge research was created. To quantify the in vitro occurrence of CTX from CTX NPs, a 110 kD cut-off dialysis film (from HiMedia Labs Pvt Ltd, Mumbai, India) was used. The setup consisted of a USP Type-II decay tester (ElectroLab TDT-08L, Bombay, India) maintained at 37°C. A phosphoric caustic is used to induce the arrangement of hydroxylpropyl cellulose (HPC) (0.005% w/v) and to reduce the pH to 4.5. The distributed HPH arrangement (0.005% with a pH of 4.5) was combined with ethanol in a mixture of 9: 1 and is used as a means of distribution to create a good state. A solution containing 0.3 mg/mL CTX was used after appropriately weakening the reconstituted CTX NPs (2 mg/mL) with 5xtrose. In order to prevent any samples from overflowing from the dialysis sac, the 7 cm long dialysis film was painstakingly filled with organized samples (0.5 mL). After the overall conclusion was fastened with a sac and the dissolving paddle was fixed with a thread guide, the device was immediately put to use. Five milliliters of the example (5 mL) were taken out at intervals of 1, 2, 4, 8, 12, 16, 20, 24, 30, 36, and 48 hours, and a new delivery medium that had been pre-equilibrated at 37°C was put in their place. The commercial strategy (Jevtana) and the delivery profile of the newly created CTX NPs were contrasted. The evaluation of CTX for discharge testing is explained using validated HPLC. A combined period-subordinate CTX discharge rate was used to display the results.

Double-checked calorimetry (DSC) (ii) A DSC instrument (Q2000, TA, New Palace, USA) was used for thermographs of CTX, SPC, monosodium citrate, sucrose and frozen CTX NPs. dry is enhanced accuracy and precision at hot temperatures by 0.05% and 0.01°. Each sample (2-4 mg) was exposed to nitrogen at -20 to 240°C (40 ml/min) while being cooked in an aluminum pan at 1°C/min. For estimates of temperature, enthalpy, and void potential, DSC is coordinated with indium.

The production of polymeric nanoparticle's (iii) By changing the surfactants and the duration of the ultrasonification in a number of definitions (A1-A4) (Table 1), polymer-coated DDA nanoparticle's were produced. To provide a prolonged drug release component that would allow DDA to be used for ant diabetic therapy, DDA was combined with polycaprolactone. The results of the current research could lead to the creation of a more effective antagonist to diabetic medication.. The characteristic qualities of nanoparticle's, such as their high viability, small size and limited diffusion, depend on several important factors. These properties of nanoparticles are essential for natural applications. The zeta potential of the nanoparticles must be greater than or equal to +/- 30 mV for them to be stable in the suspension. Expected zeta values and polydispersity lists (PDI) of all classified model. A homogenized molecule size range is

displayed in a polydispersity list of 0.2. Although the review's polydispersity was not found to be 0.150, the findings showed that the molecular homogeneity was acceptable. Drug release, cell uptake, cytotoxicity, in vivo pharmacokinetics, and biodistribution in vitro all depend significantly on physical and chemical barriers, including molecule size and surface characteristics.

Table 3: Nano-DDA's zeta potential and polydispersity index

Formulation	Zeta potential	Polydispersity index
A1	-27.8 ± 0.082	0.240 ± 0.001
A2	-26.20 ± 0.156	0.442 ± 0.036
A3	-14.026 ± 0.338	0.562 ± 0.018
A4	-32.056 ± 0.382	0.321 ± 0.028

4. RESULTS

4.1. CTX Nanoparticulate System Assessment for Various Studies

(I) In-Vitro Delivery Analysis the in vitro discharge properties of CTX NPs and Jevtana (a commercial detailing) are shown in Fig. 3. Delaying drug release from a nanoparticulate conveyance system has an advantage over currently used conventional treatments like collection in the growth and uninvolved focusing of the conveyance system.

(ii) Characterization of lyophilized CTX NPs in the strong state Using PXRD and DSC studies, the strong state of lyophilized CTX NPs was defined. A DSC study was performed to assess if the drug was genuinely solidified, indefinable, or semi crystalline in lyophilized CTX NPs. PXRD tests show that CTX is ambiguous because it has large areas of strength for no pinnacle (endotherm). The first endotherm in SPC is related to segmental movement linked to SPC unsaturated fat chains, but the subsequent endotherm at 106.02°C is attributed to polar head bunch movement.



Figure 2: Reconstituted CTX nanoparticles were analyzed for particle size using the Nicomp 380 ZLS.

(iii) Molecule Size: The mean molecule size of the organized CTX NPs was calculated using a volume weighted Gaussian circulation. A representative depiction of the size dispersion of CTX NPs is shown in Figure 2. The constructed conveyance system is a true nanoparticulate system, according to results. The majority of the particles in the drug delivery system are nanometer-sized.



Figure 3: CTX NPs and Jevtana in vitro release profiles comparison

5. CONCLUSION

Previous studies have focused on the systematic improvement of CTX stacked nanoformulations using the QbD approach to prevent the negative consequences associated with conventional

definitions. Molecular size and molecular thickness registration (PDI) were considered as influential determinants. The ongoing assessment is to assess the (ongoing) batch phase, the specifics of the trial, and to evaluate the end patient's use. Therefore, studies on drug composition estimation, molecular size, surface potential, strong state properties, in vitro drug release, similarity, imaging stability and hot cycling have certainly been studied. conducted using batch processing versions or finite dose structures. The overall findings of any investigation are satisfactory. Every single result fits perfectly inside the acknowledgment models established before the evaluation began. The nature of the definition that will be provided to disease patients is reflected in such a thorough investigation's favorable findings. Such excellent definition lowers the risk of giving patients subpar medications. This work also serves as an example of the procedure to be followed when administering a medicine delivery system to a human or a creature during preclinical or clinical trials. The results of the in vitro tests corroborate earlier findings from system DoE-based studies. A fully improved medication delivery system is produced by legitimate free and subordinate element determination, as well as its level and decision of trial configuration, and is supported by the ideal outcomes of a thorough in-vitro evaluation. Results from in vitro experiments also support earlier research that was conducted using the system DoE technique. With the right choice of independent and dependent variables, their magnitude and the best experimental setup, supported by such a definite result from extensive in vitro testing, you will have get a vastly improved drug delivery system.

REFERENCES

1. *Abouelmagd, S. A., Sun, B., Chang, A. C., Ku, Y. J., & Yeo, Y. (2016). Release kinetics study of nanoparticle-based taxane delivery system using mathematical modeling. Journal of Controlled Release, 243, 46-53.*

2. *Ahmad A, Sheikh S, Ali SM, Ahmad MU, Paithankar M, Saptarishi D, Maheshwari K, Kumar K, Singh J, Patel GN, Patel J. Development of aque ou s ba se d for mu lat ion of doce t a xel: s a fe t y a nd pharmacokinetics in patients with advanced solid tumors. Journal of Nanomedicine & Nanotechnology. 2015;6(3):1.*

3. *Bala, V., Rao, S., & Kumar, M. N. (2013). In vitro evaluation of novel taxane derivative loaded nanoparticles in breast cancer. Journal of Drug Delivery Science and Technology, 23(5), 441-447.*

4. *Beckett ST, Francesconi MG, Geary PM, Mackenzie G, Maulny AP. DSC study of sucrose melting. Carbohydrate research. 2006;341(15):2591-2599*

5. *Cooper ER. Nanoparticles: a personal experience for formulating poorly water soluble drugs. Journal of Controlled Release. 2010;141(3):300-302.*

6. *Dhaundiyal A, Jena SK, Samal SK, Sonvane B, Chand M, Sangamwar AT. Alpha-lipoic acid–stearylamine conjugate-based solid lipid nanoparticles for tamoxifen delivery: formulation, optimization, in-vivo pharmacokinetic and hepatotoxicity study. Journal of Pharmacy and Pharmacology. 2016;68(12):1535-1550.*

7. *El-Say, K. M., El-Housiny, S., & El-Kamel, A. H. (2017). Preparation, characterization, and in vitro evaluation of taxane-loaded nanoparticles for cancer chemotherapy. Drug Development and Industrial Pharmacy, 43(10), 1687-1696.*

8. *Fusser M, Øverbye A, Pandya AD, Mørch Ý, Borgos SE, Kildal W, Snipstad S, Sulheim E, Fleten KG, Askautrud HA, Engebraaten O. Cabazitaxel-loaded Poly (2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft. Journal of Controlled Release. 2019;293:183-192.*

9. *Gdowski AS, Ranjan A, Sarker MR, Vishwanatha JK. Bone-targeted cabazitaxel nanoparticles for metastatic prostate cancer skeletal lesions and pain. Nanomedicine. 2017 ;12(17):2083-2095.*

10. *Guideline IH. Validation of analytical procedures: text and methodology. Q2 (R1). 2005;1(20):5.*

11. *Gupta N, Yadav V, Patel R. A Brief Review of the Essential Role of Nanovehicles for Improving the Therapeutic Efficacy of Pharmacological Agents Against Tumours. Current Drug Delivery. 2021.*

12. *Lahiri S, Mishra BB, Ojha V, Panda N, Shukla SP, inventors; Fresenius Kabi Oncology Ltd, assignee. Amorphous form of cabazitaxel and process for its preparation. United States patent US 9,199,953. 2015.*

13. *Ma, X., Wang, L., & Liu, H. (2019). Development of a novel taxane derivative-loaded polymeric nanoparticle system for enhanced anti-cancer efficacy. Journal of Microencapsulation, 36(8), 772-779.*

14. *Mat hr usri A nnapurna M, Venk atesh B, Naga Supriya G. A validated stability-indicating liquid chromatographic method for determination of Cabazitaxel-A novel microtubule inhibitor. J Bioequiv Availab. 2014;6:134-138.*

15. *Mathrusri Annapurna M, Venkatesh B, Naga Supriya G. A validated stability-indicating liquid chromatographic method for determination of Cabazitaxel-A novel microtubule inhibitor. J Bioequiv Availab. 2014;6:134-138.*

16. *Merisko-Liversidge EM, Liversidge GG. Drug nanoparticles: formulating poorly water-soluble compounds. Toxicologic pathology. 2008;36(1):43-48.*

17. *Paithankar M, Bhalekar M. Quality by Design Enabled Development and Optimization of the Nanoparticulate System of Cabazitaxel. Int. J. Pharm. Sci. Drug Res. 2022;14(1):112-121*

18. *Singh, R., Lillard Jr, J. W., & Singh, S. (2017). Evaluation of nanoparticle-based novel taxane derivatives in breast cancer. Cancer Nanotechnology, 8(1), 6.*

19. *US Department of Health and Human Services. Food and Drug Administration Center for Drug Evaluation and Research (CDER), Guidance for Industry Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients 2005.*

20. *Zhang, X., Huang, Y., Li, H., Lu, Y., & Li, J. (2017). Formulation and characterization of a novel taxane derivative-loaded solid lipid nanoparticle for improved anticancer efficacy. Drug Development and Industrial Pharmacy, 43(7), 1131-1138.*

****